Sanofi

Irm LLC

Novartis Ag

Fangxian Sun

Maysoun Shomali

Jennifer Harris

Monsif Bouaboula

Peter McNamara

Nanxin Li

Stéphane Poirier

Zhuyan Guo

Jennifer L Harris

Peter Mcnamara

Herein are provided a combination of alpelisib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid

Herein are provided a combination of palbociclib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.

Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer

The invention provides methods for using compounds of Formula (I) for treating an EML4-ALKmediated condition such as EML4-ALKnon-small cell lung cancer, and optionally resistant to crizotinib; wherein R, R, R, R, Rand Rare as defined above.

Methods of using ALK inhibitors

Growing community of inventors

Melrose, MA, United States of America

Fangxian Sun